The 9 references in paper E. Seliverstova V., M. Krotenkova V., R. Konovalov N., S. Illarioshkin N., S. Klyushnikov A., Yu. Seliverstov A., Е. Селиверстова В., М. Кротенкова В., Р. Коновалов Н., С. Иллариошкин Н., С. Клюшников А., Ю. Селиверстов А. (2015) “КЛИНИКО-НЕЙРОВИЗУАЛИЗАЦИОННЫЙ АНАЛИЗ БОЛЕЗНИ ГЕНТИНГТОНА С ИСПОЛЬЗОВАНИЕМ ФУНКЦИОНАЛЬНОЙ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ ПОКОЯ // CLINICAL AND IMAGING ANALYSIS OF HUNTINGTON DISEASE WITH USE OF RESTING-STATE FUNCTIONAL MAGNETIC RESONANCE IMAGING” / spz:neicon:nevro:y:2015:i:3:p:11-21

1
The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993; 72(6): 971–83.
(check this in PDF content)
2
Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 2007; 16(21): 2600–15.
(check this in PDF content)
3
Block-Galarza J., Chase K.O., Sapp E., Vaughn K.T., Vallee R.B., DiFiglia M., Aronin N. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport. 1997; 8(9): 2247–50.
(check this in PDF content)
4
Pringsheim T., Wiltshire K., Day L., Dykeman J., Steeves Th., Jette N. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Movement Disord. 2012; 27(9): 1083–91.
(check this in PDF content)
5
Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A.C., Durr A., Craufurd D. et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: crosssectional analysis of baseline data. Lancet Neurol. 2009; 8(9): 791–801.
(check this in PDF content)
6
Бунятян Н.Д., Васильев А.Н., Гавришина Е.В., Ниязов Р.Р., Губенко А.И. Орфанные лекарственные препараты: США, Европейский союз и Россия. Ремедиум. Журнал о российском рынке лекарств и медицинской технике. 2013(11): 47–52.
(check this in PDF content)
7
Kremer B., Goldberg P., Andrew S.E., Theilmann J., Telenius H., Zeisler J. et al. A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 1994; 330(20): 1401–6.
(check this in PDF content)
8
Rubinsztein D.C., Leggo J., Coles R., Almqvist E., Biancalana V., Cassiman J.-J. et al. Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am. J. Hum. Genets. 1996; 59(1): 16.
(check this in PDF content)
9
Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Shelin Adam. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nature Genet. 1993; 4(4): 398-403. депрессии, ангедонии, обсессивно-компульсивным
(check this in PDF content)